Apollomics Announces Presentation at the 2024 BIO International Convention
Apollomics Announces Presentation at the 2024 BIO International Convention
FOSTER CITY, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company") (Nasdaq: APLM), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that the Company will present at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego, California.
加利福尼亚州福斯特城，2024年5月29日（GLOBE NEWSWIRE）——Apollomics Inc.（“Apollomics” 或 “公司”）（纳斯达克股票代码：APLM）是一家临床阶段的生物制药公司，正在开发多种治疗难以治疗和耐药的癌症的候选肿瘤药物，今天宣布，该公司将出席2024年6月3日至6日在圣地亚哥举行的2024 BIO国际大会，加利福尼亚州。
BIO International Convention (June 3-6, 2024)
BIO 国际大会（2024 年 6 月 3 日至 6 日）
Format: In-person
Location: San Diego, California
Presentation Date: Tuesday, June 4, 2024
Location: Theater 2 located in Hall A of the Exhibition Hall at the San Diego Convention Center
Presentation Time: 3:15 p.m.
Presenter: Sanjeev Redkar, PhD, President and Executive Director of Apollomics
格式：面对面
地点：加利福尼亚州圣地亚哥
演讲日期：2024 年 6 月 4 日，星期二
地点：2号剧院位于圣地亚哥会议中心展览厅A厅
演讲时间：下午 3:15
主持人：桑杰夫·雷德卡，博士，Apollomics总裁兼执行董事
Management will be available for one-on-one meetings with registered attendees. To schedule a meeting with the Company's management at the convention, please submit a meeting request through the BIO One-on-One Partnering system or contact brandon.weiner@westwicke.com.
管理层将可以与注册与会者进行一对一的会议。要安排在大会上与公司管理层会面，请通过BIO一对一合作系统提交会议请求或联系 brandon.weiner@westwicke.com。
About Apollomics Inc.
Apollomics Inc 公司简介
Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics currently has a pipeline of nine drug candidates across multiple programs, six of which are currently in the clinical stage of development. Apollomics' lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. For more information, please visit .
Apollomics Inc. 是一家处于临床阶段的创新生物制药公司，专注于肿瘤疗法的发现和开发，有可能与其他治疗方案相结合，利用免疫系统和靶向特定的分子途径来抑制癌症。Apollomics目前有九种候选药物在线，涵盖多个项目，其中六种目前处于临床开发阶段。Apollomics的主要项目包括vebreltinib（APL-101），一种有效的选择性c-Met抑制剂，用于治疗非小细胞肺癌和其他具有c-Met变异的晚期肿瘤，以及uproleselan（APL-106），一种特定的E-Selectin拮抗剂，有可能与标准化疗一起辅助使用来治疗急性髓系白血病。欲了解更多信息，请访问。
CONTACTS
Investor Relations
Peter Vozzo
ICR Westwicke
Peter.Vozzo@westwicke.com
+1-443-213-0505
联系人
投资者关系
彼得·沃佐
ICR Westwicke
Peter.Vozzo@westwicke.com
+1-443-213-0505
Media Relations
Sean Leous
ICR Westwicke
Sean.Leous@westwicke.com
+1-646-866-4012
媒体关系
肖恩·莱奥斯
ICR Westwicke
Sean.Leous@westwicke.com
+1-646-866-4012